| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 263.33M | 297.24M | 302.89M | 317.90M | 295.10M | 173.52M |
| Gross Profit | 37.87M | 47.49M | 49.23M | 54.12M | 55.66M | 61.28M |
| EBITDA | 36.63M | 49.16M | 52.28M | 49.02M | 49.93M | 57.51M |
| Net Income | 13.63M | 21.05M | 19.11M | 17.48M | 12.72M | 20.81M |
Balance Sheet | ||||||
| Total Assets | 374.31M | 403.91M | 385.41M | 470.90M | 383.51M | 448.31M |
| Cash, Cash Equivalents and Short-Term Investments | 7.62M | 34.27M | 26.27M | 18.46M | 146.80M | 41.07M |
| Total Debt | 1.13M | 1.63M | 161.00K | 80.56M | 6.62M | 46.09M |
| Total Liabilities | 25.86M | 36.21M | 39.44M | 120.71M | 29.98M | 87.36M |
| Stockholders Equity | 294.03M | 314.52M | 293.30M | 298.27M | 301.79M | 309.47M |
Cash Flow | ||||||
| Free Cash Flow | -5.27M | 9.00M | 35.62M | -94.36M | 174.99M | -69.88M |
| Operating Cash Flow | -3.58M | 10.66M | 37.41M | -88.15M | 187.75M | -61.51M |
| Investing Cash Flow | 20.41M | 3.97M | 2.35M | -5.87M | -12.53M | -21.67M |
| Financing Cash Flow | -37.12M | -6.76M | -30.42M | -33.52M | -68.02M | -1.55M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$147.00M | 6.26 | 8.64% | 6.71% | 2.81% | 23.68% | |
67 Neutral | HK$360.00M | 24.49 | 4.53% | 9.50% | -13.58% | -41.25% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
53 Neutral | HK$173.44M | -17.36 | -2.23% | ― | -11.79% | 25.41% | |
43 Neutral | HK$153.45M | 20.20 | 3.67% | ― | 17.91% | ― | |
41 Neutral | HK$598.49M | -25.86 | -20.27% | ― | -37.93% | -152.17% | |
39 Underperform | HK$78.11M | -1.65 | -83.05% | ― | -74.22% | 23.27% |
Tian Yuan Group Holdings Limited has announced plans to launch a new business line in mainland China’s healthcare sector, establishing a wholly owned Hong Kong subsidiary and appointing experienced medical and management professional Wu Yu as its general manager to lead strategic planning, business development and operations. The move leverages strong national policy support for healthcare under initiatives such as “Healthy China 2030” and the current Five-Year Plans, with the group aiming to capitalise on demand driven by an ageing population and rising health management needs, diversify its portfolio beyond port and oil operations, and enhance long-term shareholder value by funding this expansion from internal resources.
The most recent analyst rating on (HK:6119) stock is a Hold with a HK$0.68 price target. To see the full list of analyst forecasts on Tian Yuan Group Holdings Ltd. stock, see the HK:6119 Stock Forecast page.
Tian Yuan Group Holdings Limited has renewed its arrangements for continuing connected transactions by entering into a 2026 Terminal Services Framework Agreement with Tianyuan Petrochemical and Maoming Tianyuan, following the scheduled expiry of the 2025 agreement at the end of 2025. Under the new framework, effective from 1 January to 31 December 2026, group subsidiaries Tianyuan and Zhengyuan will continue to provide terminal uploading and unloading services to these related-party customers, with the transaction size remaining below key Listing Rules thresholds, thereby requiring reporting, announcement and annual review but not independent shareholders’ approval. The renewal secures ongoing service revenue from major connected clients while maintaining regulatory compliance, underscoring the importance of these intra-group petrochemical logistics flows to Tian Yuan’s operations and stakeholder oversight.
The most recent analyst rating on (HK:6119) stock is a Hold with a HK$0.68 price target. To see the full list of analyst forecasts on Tian Yuan Group Holdings Ltd. stock, see the HK:6119 Stock Forecast page.
Tian Yuan Group Holdings Limited has announced the resignation of Mr. Peter Chun Ming Pang from his position as joint company secretary, effective November 24, 2025. Mr. Pang’s departure is amicable, with no disagreements with the board or issues requiring attention from the Hong Kong Stock Exchange or shareholders. The remaining joint company secretary, Mr. Hung Chung Wah, will continue in his role.
The most recent analyst rating on (HK:6119) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Tian Yuan Group Holdings Ltd. stock, see the HK:6119 Stock Forecast page.
Tian Yuan Group Holdings Limited has appointed Mr. Peter Chun Ming Pang as joint company secretary, effective from November 1, 2025. Mr. Pang brings over 25 years of experience in compliance, accounting, and finance, having served in key roles at various companies and financial institutions, which is expected to enhance the company’s governance and operational efficiency.
The most recent analyst rating on (HK:6119) stock is a Buy with a HK$0.50 price target. To see the full list of analyst forecasts on Tian Yuan Group Holdings Ltd. stock, see the HK:6119 Stock Forecast page.